The pharmacologic profile of mirtazapine

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 4, 1996, Pages 19-25

  De Boer, Th ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IDAZOXAN; MIANSERIN; MIRTAZAPINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR;

DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; TRANQUILIZING ACTIVITY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AUTORECEPTORS; BEHAVIOR, ANIMAL; DEPRESSIVE DISORDER; DIOXANES; DRUG EVALUATION, PRECLINICAL; HUMANS; IDAZOXAN; IMIDAZOLES; MIANSERIN; RATS; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SYNAPTIC TRANSMISSION;

EID: 0029888880     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-525
2. Claghorn JL, Lesem MD. A double-blind placebo controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-171
3. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-196
4. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs 1995; 4(suppl 1):39-48
5. Nickolson VJ, Wieringa JH, Van Delft AML. Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn Schmiede-bergs Arch Pharmacol 1982;319:48-53
6. De Boer Th, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988;7:399-408
7. Pinder RM, Wieringa JH. Third-generation antidepressants. Med Res Rev 1993;13:259-325
8. 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994; 253:R5-R6
9. 2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995;10(suppl 2): S107-S118
10. O'Connor WT, Leonard BE. Effect on chronic administration of the 6-aza-analogue of mianserin (Org 3770) and its enantiomers on behaviour and changes in norepinephrine metabolism of olfactory-bulbectomised rats in the 'Open field' apparatus. Neuropharmacology 1985;25:267-270
11. Ruigt GSF, Engelen S, Gerrits A, el al. Computer based prediction of psychotropic drug classes based on a discriminant analysis of drug effects on rat sleep. Neuropsychobiology 1993;28:138-153
12. Ruigt GSF, Kemp B, Groenhout CM, el al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990;38:551-554
13. Andrews JS, Jansen JHM, Linders S, et al. Effect of imipramine and mirtazapine on operant performance in rats. Drug Development and Research 1994;32:58-66
14. 2-adrenoceptor blockade in the central nervous system and the effects of the enantiomers of mianserin and its aza-analogue Org 3770. Arch Int Pharmacodyn Ther 1988;291:185-201
15. 3 receptors in cultured mouse neuroblastomacells. Neuropharmacology 1994;33:501-510
16. 1A receptors induces lower lip retraction in rat. Pharmacol Biochem Behav 1989;33:821-827
17. 2A receptors after chronic treatment with Remeron [letter], Eur Neuro-psychopharmacol 1995;5:306
18. Frazer A. Antidepressant drugs. Depression 1994;2:1-19
19. 2 receptors in the regulation of sleep and wakefulness in the rat. Psychopharmacology (Berl) 1989;97:436-442
20. 2-adrenergic agonist clonidine. Brain Res 1975;92:291-306
21. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980;19:355-363
22. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226
23. 1-adrenoceptor antagonists differentially control release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994;261:59-64
24. Clement H-H, Gemsa D, Wesemann W. The effect of adrenergic drugs on serotonin metabolism in the nucleus raphe dorsalis of the rat, studied by in vivo voltammetry. Eur J Pharmacol 1992;217:43-48
25. Quintin L, Hilaire G, Pujol JF. Variations in 3,4-dihydroxyphenylacetic acid concentrations are correlated to single cell firing changes in the rat locus coeruleus. Neuroscience 1986;18:889-899
26. Vahabzadeh A, Fillenz M. Studies on the origin of rat hippocampal dihydroxyphenylacetic acid using microdialysis. Neurosci Lett 1992;136: 51-55
27. Ortemann C, Robert F, Renaud B, et al. In vivo microdialysis study of the extracellular 3,4-dihydroxyphenylacetic acid in the rat locus coeruleus: topographical and pharmacological aspects. J Neurochem 1993;61:594-601
28. Doxey JC, Roach AG, Smith CFC. Studies on RX 781094: a selective, potent and specific antagonist of adrenoceptors. Br J Pharmacol 1983;78: 489-505
29. 2-adrenoceptor antagonist Org 3770 on rat 5-HT neurotransmission. Society for Neuroscience Abstracts 1994;20:1553
30. 2-adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat. J Pharmacol Exp Ther. In press
31. de Montigny C, Haddjeri N, Mongeau R, et al. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs 1995;4(suppl 1):13-17
32. Gothert M, Huth H, Schlicker E. Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol 1981;317:199-203
33. 3H-5-hydroxytryptamine release from rat hippocampus. Eur J Pharmacol 1982;81:97-106
34. Maura G, Gemignani A, Raiteri M. Noradrenaline inhibits central serotonin release through -adrenoceptors located on serotonergic nerve terminals. Naunyn Schmiedebergs Arch Pharmacol 1982;320:272-274
35. 3H]5-HT release after noradrenergic denervation with dsp4. Eur J Pharmacol 1985;119:131-133
36. 2-Adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn Schmiedebergs Arch Pharmacol 1992;345:137-143
37. 2-adrenergic heteroreceptors of 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1993;347:266-272
38. Chaput Y, Blier P, de Montigny C. In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J Neurosci 1986;6:2796-2801
39. 2-antagonist antidepressants, Remeron (Org 3770) and mianserin on noradrenergic and serotonin transmission in vivo [letter]. Can J Physiol Pharmacol 1994;72(suppl 1):439
40. Preziosi P, Martire M, Navarra P, et al. Prolactin-lowering ability of (±)-idazoxan may be linked to a central noradrenergic-serotonergic interplay. J Pharmacol Exp Ther 1989;249:256-263
41. Kawai N, Jamamoto T, Baba A, et al. Inhibitory effect of idazoxan on forskoline-stimulated adenylate cyclase activity through 5-hydroxytryptamine receptors. Drug Res 1994;44:1-3
42. 3 receptor antagonists. Int Clin Psychopharmacol 1993;8(suppl 2):3-9
43. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994;10:18-46
44. Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994;55(2, suppl):34-44
45. Finley PR. Selective serotonin reuptake inhibition: pharmacological profiles and potential therapeutic distinctions. Ann Pharmacother 1994;28: 1359-1369
46. Leonard BE. Serotonin receptors: where are they going? Int Clin Psychopharmacol 1994;9(suppl 1P):7-17
47. Norman TR, McGrath CJ, Burrows GD. The neurochemical and behavioural effects of the isomers of mirtazapine in normal rats [letter]. Eur Neuropsychopharmacol 1995;5:316
48. Berendsen HHG, Broekkamp CLE. Behavioral evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 1990;101:667-673